+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
IVD & LDT For Autoimmune Diseases Market by Product Type, Test Type, Technology, Sample Type, Application, End User, Distribution Channel - Global Forecast 2026-2032- Product Image
IVD & LDT For Autoimmune Diseases Market by Product Type, Test Type, Technology, Sample Type, Application, End User, Distribution Channel - Global Forecast 2026-2032- Product Image
Sale

IVD & LDT For Autoimmune Diseases Market by Product Type, Test Type, Technology, Sample Type, Application, End User, Distribution Channel - Global Forecast 2026-2032

  • Report

  • 184 Pages
  • June 2026
  • Region: Global
  • 360iResearch™
  • ID: 5674356
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The IVD & LDT For Autoimmune Diseases Market is projected to reach USD 19.69 Billion in 2026. It is expected to continue growing at a CAGR of 7.15%, reaching USD 29.85 Billion by 2032.

Autoimmune disease diagnostics sit at the intersection of high clinical need, expanding test menus, and tightening regulatory oversight. More than 80 autoimmune diseases are recognized, including rheumatoid arthritis, systemic lupus erythematosus, celiac disease, autoimmune thyroid disease, inflammatory bowel disease, and type 1 diabetes. Diagnosis often requires a combination of clinical assessment, autoantibody testing, inflammatory markers, histopathology, imaging, and, in selected cases, molecular or genetic assays.

The IVD and LDT ecosystem is central to earlier detection, differential diagnosis, disease stratification, and therapy monitoring. Core autoimmune IVD categories include antinuclear antibody testing, extractable nuclear antigen panels, anti-CCP assays, anti-dsDNA testing, antiphospholipid antibody panels, tissue transglutaminase assays, thyroid autoantibodies, complement testing, and multiplex immunoassays. Laboratory-developed tests continue to support specialized autoimmune diagnostics where rare disease complexity, low-volume indications, or rapidly evolving biomarkers make standardized commercial kits less available.

Demand is reinforced by aging populations, improved disease awareness, wider access to specialist care, and the clinical consequences of delayed diagnosis. In the United States, the National Institutes of Health has cited autoimmune diseases as affecting more than 24 million people, while population studies have documented rising antinuclear antibody prevalence over time. These signals support sustained investment in autoimmune disease testing, quality systems, digital laboratory infrastructure, and evidence-based biomarker validation.

Transformative Shifts in the Autoimmune Diagnostics Landscape

The autoimmune diagnostics landscape is shifting from single-analyte, symptom-triggered testing toward integrated, data-rich diagnostic pathways. Laboratories and manufacturers are expanding from traditional indirect immunofluorescence and ELISA methods into chemiluminescence immunoassays, line immunoassays, multiplex bead-based platforms, microarrays, and automated workflow systems. These technologies improve throughput, reproducibility, and panel-based interpretation, especially in high-volume areas such as ANA reflex testing, rheumatoid arthritis serology, celiac disease screening, and autoimmune thyroid testing.

Regulatory transformation is one of the defining shifts. In the United States, the FDA issued its 2024 final rule to phase out the general enforcement discretion approach for many laboratory-developed tests, increasing the importance of analytical validity, clinical validity, quality management, and post-market oversight. In Europe, the In Vitro Diagnostic Regulation has raised evidence and conformity assessment expectations, particularly for higher-risk diagnostics and companion diagnostics. These reforms are pushing laboratories, IVD manufacturers, and health systems to strengthen documentation, validation, traceability, and clinical performance evidence.

Commercial models are also changing. Reference laboratories, hospital networks, and diagnostic manufacturers are moving toward integrated test utilization management, reflex algorithms, clinical decision support, and digital reporting. The result is a market where differentiation depends not only on assay sensitivity and specificity but also on turnaround time, interpretive clarity, reimbursement alignment, automation compatibility, and proven clinical utility.

Cumulative Impact of Artificial Intelligence on IVD and LDT Workflows

Artificial intelligence is increasingly influencing autoimmune IVD and LDT workflows, although adoption is uneven and strongest where structured datasets, image analysis, and rule-based interpretation already exist. AI-enabled pattern recognition can support ANA immunofluorescence interpretation, reduce inter-reader variability, and improve workflow efficiency in laboratories managing high test volumes. Machine learning models are also being evaluated for combining autoantibody profiles, inflammatory markers, demographics, symptoms, and longitudinal laboratory values to support differential diagnosis and risk stratification.

The cumulative impact of AI is most practical when it enhances, rather than replaces, validated diagnostic processes. In autoimmune testing, false positives and nonspecific autoantibody findings are common clinical challenges; AI can help by incorporating pretest probability, reflex testing rules, and evidence-based reporting logic. This can reduce unnecessary downstream testing and improve the consistency of recommendations across decentralized health systems.

AI adoption must remain anchored in regulatory-grade validation, bias assessment, cybersecurity, and clinical governance. The FDA maintains a public list of AI- and machine learning-enabled medical devices, demonstrating regulatory attention to software-driven diagnostics, while global authorities continue to refine expectations for transparency and lifecycle management. For autoimmune diagnostics, the near-term opportunity is operationally focused: faster image review, smarter reflex pathways, quality control monitoring, and improved physician-facing interpretation.

Key Regional Insights Across North America, Europe, Asia-Pacific, and Emerging Markets

North America remains a leading region for autoimmune IVD and LDT adoption due to high healthcare spending, broad access to specialty laboratories, established reimbursement structures, and a large base of CLIA-certified laboratories. The United States drives innovation in LDT development, reference laboratory scale, and digital test ordering, while Canada supports adoption through publicly funded healthcare systems and provincial laboratory networks. The region is also experiencing a major compliance shift as FDA oversight of many LDTs becomes more formalized.

Europe is shaped by strong clinical guidelines, advanced hospital laboratory infrastructure, and the implementation of the EU IVDR. Germany, France, Italy, Spain, and the Nordic countries are important markets for automated immunoassay systems, autoimmune panels, and standardized laboratory quality frameworks. The United Kingdom, while outside the European Union, continues to be influential through NHS procurement, health technology assessment, and centralized diagnostic initiatives.

Asia-Pacific is one of the fastest-evolving regions for autoimmune disease diagnostics, supported by large patient populations, expanding private healthcare, increasing specialist access, and investment in laboratory automation. China, Japan, India, South Korea, and Australia represent distinct growth pathways, ranging from high-volume hospital testing and domestic IVD manufacturing to advanced reference laboratory networks. Latin America, led by Brazil and Mexico, is expanding access to autoimmune testing through private laboratories and tertiary care centers, although reimbursement variability and uneven specialist distribution remain constraints. The Middle East is investing in advanced diagnostic infrastructure through GCC healthcare modernization programs, particularly in hospital automation and reference laboratory development. Africa remains earlier in adoption, with opportunities centered on laboratory capacity building, affordable assays, workforce training, and regional reference testing models that improve access beyond major urban centers.

Key Group Insights for G7, EU, BRICS, ASEAN, GCC, and NATO Markets

The G7 economies play a central role in autoimmune IVD innovation because they combine advanced healthcare infrastructure, strong regulatory systems, high diagnostic utilization, and mature reimbursement assessment. The United States, Japan, Germany, France, Italy, Canada, and the United Kingdom are influential in assay validation, clinical guideline development, automation adoption, and evidence generation. Their laboratories are also among the earliest adopters of digital pathology, AI-assisted interpretation, laboratory information system connectivity, and integrated clinical decision support.

The European Union is a pivotal group because the IVDR has changed market access requirements for IVD manufacturers and clinical laboratories serving EU member states. Stronger clinical evidence, post-market surveillance, and notified body involvement are reshaping product portfolios and encouraging a focus on well-validated autoimmune assays. NATO countries overlap significantly with North American and European markets, creating common demand for resilient supply chains, cybersecurity, standardized laboratory readiness, and continuity of diagnostic services across civilian and defense-linked health systems.

BRICS countries represent scale and long-term demand expansion, particularly through China, India, and Brazil, while Russia and South Africa add regional diagnostic capacity and localized healthcare priorities. These markets are expanding laboratory networks, domestic IVD production, and access to specialist diagnostics, although affordability and regional disparities remain important. ASEAN is gaining relevance as Singapore, Malaysia, Thailand, Indonesia, Vietnam, and the Philippines invest in private healthcare, medical tourism, public laboratory modernization, and specialty care access. The GCC is advancing through high-spending healthcare systems in Saudi Arabia, the United Arab Emirates, Qatar, Kuwait, Bahrain, and Oman, where premium diagnostics, hospital automation, reference laboratory partnerships, and national health transformation programs are increasingly important.

Key Country Insights for Major Autoimmune IVD and LDT Markets

The United States is the most influential country market for autoimmune LDTs because of its large reference laboratory sector, CLIA framework, specialist physician base, and rapid adoption of advanced assays. FDA’s 2024 LDT final rule is reshaping compliance strategies, validation investments, and partnerships between laboratories and IVD manufacturers. Canada shows steady demand through provincial health systems and accredited laboratory networks, while Mexico is expanding autoimmune testing through private laboratories and urban hospital networks. Brazil leads Latin America with a large population, established private diagnostics infrastructure, tertiary care capacity, and growing access to immunology testing.

In Europe, Germany benefits from advanced laboratory automation, strong hospital infrastructure, and a major diagnostics manufacturing base. France, Italy, and Spain show sustained demand for autoimmune serology across rheumatology, gastroenterology, endocrinology, dermatology, neurology, and nephrology pathways. The United Kingdom remains important through NHS laboratory networks, health technology assessment, and centralized procurement models. Russia has domestic diagnostic capacity and demand for autoimmune testing, but international supply dynamics, localization requirements, and regulatory complexity can influence access to advanced platforms.

In Asia-Pacific, China combines large testing volumes, expanding hospital infrastructure, domestic IVD manufacturing scale, and policy support for local medical technology capability. India is growing through private diagnostic chains, rising specialist access, expanding urban healthcare networks, and increasing autoimmune disease awareness, although affordability and geographic variation remain challenges. Japan and South Korea are mature, technology-forward markets with high laboratory quality expectations, strong automation adoption, and advanced hospital-based diagnostic pathways. Australia supports advanced autoimmune diagnostics through public-private laboratory networks, specialist care pathways, national quality assurance practices, and broad use of standardized laboratory accreditation systems.

Actionable Recommendations for Autoimmune Diagnostics Industry Leaders

Industry leaders should prioritize evidence generation, regulatory readiness, and clinically meaningful differentiation. Autoimmune assays must demonstrate analytical performance, clinical validity, reproducibility, and clear interpretive value across diverse patient populations. Organizations should prepare for more demanding regulatory expectations by strengthening design controls, validation documentation, quality management systems, post-market surveillance, and real-world performance monitoring.

Commercial success will depend on workflow integration. Manufacturers and laboratories should develop autoimmune testing solutions that support reflex algorithms, automated sample handling, laboratory information system connectivity, digital result interpretation, and clinician-friendly reporting. In high-volume segments, automation and turnaround time can be decisive; in rare or complex autoimmune diseases, scientific credibility and specialist interpretation are more important.

Research Methodology for Evidence-Based Autoimmune IVD and LDT Analysis

This executive summary is built on a structured secondary research methodology aligned with healthcare market intelligence standards. The analysis synthesizes information from regulatory agencies, public health institutions, peer-reviewed literature, clinical laboratory standards, public disclosures, and recognized healthcare organizations. Key reference areas include FDA IVD and LDT policy, EU IVDR implementation, CLIA laboratory oversight, NIH autoimmune disease information, population-based autoantibody studies, clinical practice guidelines, and published evidence on autoimmune biomarker testing.

The research approach emphasizes triangulation across regulatory, clinical, technological, and commercial signals. Market direction is assessed by reviewing diagnostic platform evolution, laboratory automation trends, test utilization patterns, reimbursement considerations, and regional healthcare infrastructure. Country and regional insights are interpreted through healthcare access, laboratory capacity, regulatory maturity, disease awareness, specialist availability, and adoption of advanced immunoassay and molecular diagnostic technologies.

No unsupported market sizing claims are used in this summary. All conclusions are framed around verifiable industry drivers, documented regulatory changes, recognized clinical needs, and observable technology trends affecting autoimmune IVDs and laboratory-developed tests.

Conclusion: Evidence, Automation, and Compliance Define Future Growth

The IVD and LDT market for autoimmune diseases is entering a more evidence-driven, technology-enabled, and regulated phase. Rising clinical demand, improved awareness, and the complexity of autoimmune diagnosis are supporting continued need for accurate autoantibody testing, multiplex panels, automated immunoassays, and specialized laboratory-developed tests.

The strongest opportunities will favor organizations that combine scientific validity with operational excellence. Regulatory changes in the United States and Europe are raising expectations, while Asia-Pacific, Latin America, the Middle East, and Africa are expanding diagnostic access at different speeds. AI will add value where it improves reproducibility, workflow efficiency, and clinical interpretation within validated laboratory systems.

For industry leaders, the strategic priority is clear: build trustworthy autoimmune diagnostics that are clinically useful, scalable, compliant, and integrated into real-world care pathways. Organizations that align innovation with evidence, quality, and physician decision-making will be best positioned to compete in the evolving autoimmune disease diagnostics market.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. IVD & LDT For Autoimmune Diseases Market, by Product Type
7.1. In Vitro Diagnostic
7.2. Lab Developed Test
8. IVD & LDT For Autoimmune Diseases Market, by Test Type
8.1. Antinuclear Antibody (ANA) Tests
8.1.1. ELISA-based ANA
8.1.2. IFA-based ANA
8.2. Autoantibody Tests
8.2.1. Anti-dsDNA
8.2.2. Anti-CCP
8.2.3. Anti-ENA Panel
8.3. Inflammatory Marker Tests
8.3.1. CRP
8.3.2. ESR
8.4. Genetic Tests
8.4.1. HLA Typing
8.4.2. SNP-based Testing
9. IVD & LDT For Autoimmune Diseases Market, by Technology
9.1. Immunoassay
9.1.1. ELISA
9.1.2. CLIA
9.1.3. RIA
9.1.4. FIA
9.2. Molecular Diagnostics
9.2.1. PCR
9.2.2. NGS
9.2.3. Microarrays
9.3. Flow Cytometry
9.4. Immunofluorescence
10. IVD & LDT For Autoimmune Diseases Market, by Sample Type
10.1. Tissue Biopsies
10.2. Saliva
10.3. Urine
10.4. Blood
10.4.1. Serum
10.4.2. Plasma
11. IVD & LDT For Autoimmune Diseases Market, by Application
11.1. Celiac Disease
11.2. Multiple Sclerosis
11.3. Rheumatoid Arthritis
11.4. Systemic Lupus Erythematosus
11.5. Type 1 Diabetes
12. IVD & LDT For Autoimmune Diseases Market, by End User
12.1. Academic & Research Institutes
12.2. Diagnostic Laboratories
12.3. Hospital
12.3.1. Public
12.3.2. Private
12.4. Reference Laboratories
13. IVD & LDT For Autoimmune Diseases Market, by Distribution Channel
13.1. Offline
13.2. Online
14. Asia-Pacific IVD & LDT For Autoimmune Diseases Market
15. Europe IVD & LDT For Autoimmune Diseases Market
16. North America IVD & LDT For Autoimmune Diseases Market
17. Latin America IVD & LDT For Autoimmune Diseases Market
18. Africa IVD & LDT For Autoimmune Diseases Market
19. Middle East IVD & LDT For Autoimmune Diseases Market
20. NATO IVD & LDT For Autoimmune Diseases Market
21. G7 IVD & LDT For Autoimmune Diseases Market
22. BRICS IVD & LDT For Autoimmune Diseases Market
23. European Union IVD & LDT For Autoimmune Diseases Market
24. ASEAN IVD & LDT For Autoimmune Diseases Market
25. GCC IVD & LDT For Autoimmune Diseases Market
26. China IVD & LDT For Autoimmune Diseases Market
27. United States IVD & LDT For Autoimmune Diseases Market
28. Japan IVD & LDT For Autoimmune Diseases Market
29. India IVD & LDT For Autoimmune Diseases Market
30. Germany IVD & LDT For Autoimmune Diseases Market
31. United Kingdom IVD & LDT For Autoimmune Diseases Market
32. Australia IVD & LDT For Autoimmune Diseases Market
33. France IVD & LDT For Autoimmune Diseases Market
34. South Korea IVD & LDT For Autoimmune Diseases Market
35. Italy IVD & LDT For Autoimmune Diseases Market
36. Canada IVD & LDT For Autoimmune Diseases Market
37. Russia IVD & LDT For Autoimmune Diseases Market
38. Brazil IVD & LDT For Autoimmune Diseases Market
39. Mexico IVD & LDT For Autoimmune Diseases Market
40. Spain IVD & LDT For Autoimmune Diseases Market
41. Competitive Landscape
41.1. Market Concentration Analysis, 2025
41.1.1. Concentration Ratio (CR)
41.1.2. Herfindahl Hirschman Index (HHI)
41.2. Recent Developments & Impact Analysis, 2025
41.3. Product Portfolio Analysis, 2025
41.4. Benchmarking Analysis, 2025
42. Company Profiles
42.1. A. Menarini Diagnostics s.r.l.
42.2. Abbott Laboratories
42.3. Adaptive Biotechnologies Corporation
42.4. AESKU.GROUP GmbH & Co. KG
42.5. Agilent Technologies, Inc.
42.6. Bio-Rad Laboratories, Inc.
42.7. bioMérieux S.A.
42.8. Corgenix, Inc.
42.9. Danaher Corporation
42.10. DiaSorin S.p.A.
42.11. EUROIMMUN Medizinische Labordiagnostika AG
42.12. Exagen Inc.
42.13. F. Hoffmann-La Roche Ltd
42.14. Gold Standard Diagnostics
42.15. Grifols, S.A.
42.16. Hycor Biomedical LLC
42.17. Inova Diagnostics, Inc.
42.18. KRONUS
42.19. LabCorp
42.20. Myriad Genetics, Inc.
42.21. Omega Diagnostics Group plc
42.22. Quest Diagnostics Incorporated
42.23. QuidelOrtho Corporation
42.24. Revvity, Inc.
42.25. Sebia
42.26. Seramun Diagnostica GmbH
42.27. Siemens Healthineers AG
42.28. Thermo Fisher Scientific Inc.
42.29. Werfen S.A.
List of Figures
FIGURE 1. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 7. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 9. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 13. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
FIGURE 14. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
FIGURE 15. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2025 VS 2032 (%)
FIGURE 17. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
FIGURE 19. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2032 (%)
FIGURE 21. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 23. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 25. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 27. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 29. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 30. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 31. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 32. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 33. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 34. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 35. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 36. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 37. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 38. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 39. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 40. NATO IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 41. NATO IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 42. G7 IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 43. G7 IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 44. BRICS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 45. BRICS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 46. EUROPEAN UNION IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 47. EUROPEAN UNION IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 48. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 49. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 50. GCC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 51. GCC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 52. CHINA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 53. UNITED STATES IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 54. JAPAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 55. INDIA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 56. GERMANY IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 57. UNITED KINGDOM IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 58. AUSTRALIA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 59. FRANCE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 60. SOUTH KOREA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 61. ITALY IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 62. CANADA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 63. RUSSIA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 64. BRAZIL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 65. MEXICO IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 66. SPAIN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SHARE, BY KEY PLAYER, 2025
TABLE 7. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
TABLE 8. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL IN VITRO DIAGNOSTIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL IN VITRO DIAGNOSTIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL IN VITRO DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL LAB DEVELOPED TEST MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL LAB DEVELOPED TEST MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL LAB DEVELOPED TEST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL ANTINUCLEAR ANTIBODY (ANA) TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL ANTINUCLEAR ANTIBODY (ANA) TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL ANTINUCLEAR ANTIBODY (ANA) TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL ELISA-BASED ANA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL ELISA-BASED ANA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL ELISA-BASED ANA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL IFA-BASED ANA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL IFA-BASED ANA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL IFA-BASED ANA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL AUTOANTIBODY TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL AUTOANTIBODY TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL AUTOANTIBODY TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL ANTI-DSDNA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL ANTI-DSDNA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL ANTI-DSDNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL ANTI-CCP MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL ANTI-CCP MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL ANTI-CCP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL ANTI-ENA PANEL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL ANTI-ENA PANEL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL ANTI-ENA PANEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL INFLAMMATORY MARKER TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL INFLAMMATORY MARKER TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL INFLAMMATORY MARKER TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL CRP MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL CRP MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL CRP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL ESR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL ESR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL ESR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL GENETIC TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL GENETIC TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL GENETIC TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL HLA TYPING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL HLA TYPING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL HLA TYPING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL SNP-BASED TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL SNP-BASED TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL SNP-BASED TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL IMMUNOASSAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL IMMUNOASSAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL ELISA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL ELISA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL ELISA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL CLIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL CLIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL CLIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL RIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL RIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL RIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL FIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL FIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL FIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL PCR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL PCR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL PCR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL NGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL NGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL NGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL MICROARRAYS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL MICROARRAYS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL MICROARRAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL FLOW CYTOMETRY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL FLOW CYTOMETRY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL FLOW CYTOMETRY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL IMMUNOFLUORESCENCE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL IMMUNOFLUORESCENCE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL IMMUNOFLUORESCENCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL TISSUE BIOPSIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL TISSUE BIOPSIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL TISSUE BIOPSIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL SALIVA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL SALIVA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL SALIVA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL URINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL URINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL URINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL BLOOD MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL BLOOD MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL BLOOD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL SERUM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL SERUM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL SERUM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL PLASMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL PLASMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL PLASMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL CELIAC DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL CELIAC DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL CELIAC DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 114. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 115. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 116. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 117. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 118. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 119. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 120. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 121. GLOBAL TYPE 1 DIABETES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 122. GLOBAL TYPE 1 DIABETES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 123. GLOBAL TYPE 1 DIABETES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 124. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 125. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 126. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 127. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 128. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 129. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 130. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 131. GLOBAL HOSPITAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 132. GLOBAL HOSPITAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 133. GLOBAL HOSPITAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 134. GLOBAL PUBLIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 135. GLOBAL PUBLIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 136. GLOBAL PUBLIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 137. GLOBAL PRIVATE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 138. GLOBAL PRIVATE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 139. GLOBAL PRIVATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 140. GLOBAL REFERENCE LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 141. GLOBAL REFERENCE LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 142. GLOBAL REFERENCE LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 143. GLOBAL IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 144. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 145. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 146. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 147. GLOBAL ONLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 148. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 149. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 150. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 151. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 152. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 153. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ANTINUCLEAR ANTIBODY (ANA) TESTS, 2018-2032 (USD MILLION)
TABLE 154. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY AUTOANTIBODY TESTS, 2018-2032 (USD MILLION)
TABLE 155. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY INFLAMMATORY MARKER TESTS, 2018-2032 (USD MILLION)
TABLE 156. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY GENETIC TESTS, 2018-2032 (USD MILLION)
TABLE 157. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 158. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
TABLE 159. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 160. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 161. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
TABLE 162. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 163. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 164. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
TABLE 165. ASIA-PACIFIC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 166. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 167. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 168. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 169. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ANTINUCLEAR ANTIBODY (ANA) TESTS, 2018-2032 (USD MILLION)
TABLE 170. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY AUTOANTIBODY TESTS, 2018-2032 (USD MILLION)
TABLE 171. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY INFLAMMATORY MARKER TESTS, 2018-2032 (USD MILLION)
TABLE 172. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY GENETIC TESTS, 2018-2032 (USD MILLION)
TABLE 173. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 174. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
TABLE 175. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 176. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 177. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
TABLE 178. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 179. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 180. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
TABLE 181. EUROPE IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 182. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 183. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 184. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 185. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ANTINUCLEAR ANTIBODY (ANA) TESTS, 2018-2032 (USD MILLION)
TABLE 186. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY AUTOANTIBODY TESTS, 2018-2032 (USD MILLION)
TABLE 187. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY INFLAMMATORY MARKER TESTS, 2018-2032 (USD MILLION)
TABLE 188. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY GENETIC TESTS, 2018-2032 (USD MILLION)
TABLE 189. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 190. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
TABLE 191. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 192. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 193. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
TABLE 194. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 195. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 196. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
TABLE 197. NORTH AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 198. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 199. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 200. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 201. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ANTINUCLEAR ANTIBODY (ANA) TESTS, 2018-2032 (USD MILLION)
TABLE 202. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY AUTOANTIBODY TESTS, 2018-2032 (USD MILLION)
TABLE 203. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY INFLAMMATORY MARKER TESTS, 2018-2032 (USD MILLION)
TABLE 204. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY GENETIC TESTS, 2018-2032 (USD MILLION)
TABLE 205. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 206. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
TABLE 207. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 208. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 209. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
TABLE 210. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 211. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 212. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
TABLE 213. LATIN AMERICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 214. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 215. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 216. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 217. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ANTINUCLEAR ANTIBODY (ANA) TESTS, 2018-2032 (USD MILLION)
TABLE 218. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY AUTOANTIBODY TESTS, 2018-2032 (USD MILLION)
TABLE 219. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY INFLAMMATORY MARKER TESTS, 2018-2032 (USD MILLION)
TABLE 220. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY GENETIC TESTS, 2018-2032 (USD MILLION)
TABLE 221. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 222. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
TABLE 223. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 224. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 225. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
TABLE 226. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 227. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 228. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
TABLE 229. AFRICA IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 230. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 231. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 232. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 233. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ANTINUCLEAR ANTIBODY (ANA) TESTS, 2018-2032 (USD MILLION)
TABLE 234. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY AUTOANTIBODY TESTS, 2018-2032 (USD MILLION)
TABLE 235. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY INFLAMMATORY MARKER TESTS, 2018-2032 (USD MILLION)
TABLE 236. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY GENETIC TESTS, 2018-2032 (USD MILLION)
TABLE 237. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 238. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
TABLE 239. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 240. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 241. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
TABLE 242. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 243. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 244. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
TABLE 245. MIDDLE EAST IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 246. NATO IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 247. NATO IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 248. NATO IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 249. NATO IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ANTINUCLEAR ANTIBODY (ANA) TESTS, 2018-2032 (USD MILLION)
TABLE 250. NATO IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY AUTOANTIBODY TESTS, 2018-2032 (USD MILLION)
TABLE 251. NATO IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY INFLAMMATORY MARKER TESTS, 2018-2032 (USD MILLION)
TABLE 252. NATO IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY GENETIC TESTS, 2018-2032 (USD MILLION)
TABLE 253. NATO IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 254. NATO IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
TABLE 255. NATO IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 256. NATO IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 257. NATO IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
TABLE 258. NATO IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 259. NATO IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 260. NATO IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
TABLE 261. NATO IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 262. G7 IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 263. G7 IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 264. G7 IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 265. G7 IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ANTINUCLEAR ANTIBODY (ANA) TESTS, 2018-2032 (USD MILLION)
TABLE 266. G7 IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY AUTOANTIBODY TESTS, 2018-2032 (USD MILLION)
TABLE 267. G7 IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY INFLAMMATORY MARKER TESTS, 2018-2032 (USD MILLION)
TABLE 268. G7 IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY GENETIC TESTS, 2018-2032 (USD MILLION)
TABLE 269. G7 IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 270. G7 IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
TABLE 271. G7 IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 272. G7 IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 273. G7 IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
TABLE 274. G7 IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 275. G7 IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 276. G7 IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
TABLE 277. G7 IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 278. BRICS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 279. BRICS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 280. BRICS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 281. BRICS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ANTINUCLEAR ANTIBODY (ANA) TESTS, 2018-2032 (USD MILLION)
TABLE 282. BRICS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY AUTOANTIBODY TESTS, 2018-2032 (USD MILLION)
TABLE 283. BRICS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY INFLAMMATORY MARKER TESTS, 2018-2032 (USD MILLION)
TABLE 284. BRICS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY GENETIC TESTS, 2018-2032 (USD MILLION)
TABLE 285. BRICS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 286. BRICS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
TABLE 287. BRICS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 288. BRICS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 289. BRICS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
TABLE 290. BRICS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 291. BRICS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 292. BRICS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
TABLE 293. BRICS IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 294. EUROPEAN UNION IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 295. EUROPEAN UNION IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 296. EUROPEAN UNION IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 297. EUROPEAN UNION IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ANTINUCLEAR ANTIBODY (ANA) TESTS, 2018-2032 (USD MILLION)
TABLE 298. EUROPEAN UNION IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY AUTOANTIBODY TESTS, 2018-2032 (USD MILLION)
TABLE 299. EUROPEAN UNION IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY INFLAMMATORY MARKER TESTS, 2018-2032 (USD MILLION)
TABLE 300. EUROPEAN UNION IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY GENETIC TESTS, 2018-2032 (USD MILLION)
TABLE 301. EUROPEAN UNION IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 302. EUROPEAN UNION IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
TABLE 303. EUROPEAN UNION IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 304. EUROPEAN UNION IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 305. EUROPEAN UNION IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
TABLE 306. EUROPEAN UNION IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 307. EUROPEAN UNION IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 308. EUROPEAN UNION IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
TABLE 309. EUROPEAN UNION IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 310. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 311. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 312. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 313. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ANTINUCLEAR ANTIBODY (ANA) TESTS, 2018-2032 (USD MILLION)
TABLE 314. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY AUTOANTIBODY TESTS, 2018-2032 (USD MILLION)
TABLE 315. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY INFLAMMATORY MARKER TESTS, 2018-2032 (USD MILLION)
TABLE 316. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY GENETIC TESTS, 2018-2032 (USD MILLION)
TABLE 317. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 318. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
TABLE 319. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 320. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 321. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
TABLE 322. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 323. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 324. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
TABLE 325. ASEAN IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 326. GCC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 327. GCC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 328. GCC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
TABLE 329. GCC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY ANTINUCLEAR ANTIBODY (ANA) TESTS, 2018-2032 (USD MILLION)
TABLE 330. GCC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY AUTOANTIBODY TESTS, 2018-2032 (USD MILLION)
TABLE 331. GCC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY INFLAMMATORY MARKER TESTS, 2018-2032 (USD MILLION)
TABLE 332. GCC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY GENETIC TESTS, 2018-2032 (USD MILLION)
TABLE 333. GCC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
TABLE 334. GCC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
TABLE 335. GCC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
TABLE 336. GCC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
TABLE 337. GCC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
TABLE 338. GCC IVD & LDT FOR AUTOIMMUNE DISEASES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 339. GCC IVD &

Companies Mentioned

The companies featured in this IVD & LDT For Autoimmune Diseases market report include:
  • A. Menarini Diagnostics s.r.l.
  • Abbott Laboratories
  • Adaptive Biotechnologies Corporation
  • AESKU.GROUP GmbH & Co. KG
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • bioMérieux S.A.
  • Corgenix, Inc.
  • Danaher Corporation
  • DiaSorin S.p.A.
  • EUROIMMUN Medizinische Labordiagnostika AG
  • Exagen Inc.
  • F. Hoffmann-La Roche Ltd
  • Gold Standard Diagnostics
  • Grifols, S.A.
  • Hycor Biomedical LLC
  • Inova Diagnostics, Inc.
  • KRONUS
  • LabCorp
  • Myriad Genetics, Inc.
  • Omega Diagnostics Group plc
  • Quest Diagnostics Incorporated
  • QuidelOrtho Corporation
  • Revvity, Inc.
  • Sebia
  • Seramun Diagnostica GmbH
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • Werfen S.A.

Table Information

Report AttributeDetails
No. of Pages184
PublishedJune 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 19.69 Billion
Forecasted Market Value ( USD ) by 2032 $ 29.85 Billion
Compound Annual Growth Rate7.1%
Regions CoveredGlobal
No. of Companies Mentioned30

Related Topics

Related Reports

Autoimmune Disease Diagnosis - Global Strategic Business Report - Product Image

Autoimmune Disease Diagnosis - Global Strategic Business Report

  • Report
  • 369 Pages
  • Global
From
Autoimmune Disease Diagnosis Market Size, Share, Trends and Forecast by Product Type, Disease Type, Test Type, End-User, and Region, 2026-2034 - Product Image

Autoimmune Disease Diagnosis Market Size, Share, Trends and Forecast by Product Type, Disease Type, Test Type, End-User, and Region, 2026-2034

  • Report
  • 139 Pages
  • Global
From
Autoimmune Disease Diagnosis Market Report 2026 - Product Image

Autoimmune Disease Diagnosis Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Autoimmune Disease Testing Market - Forecast from 2026 to 2031 - Product Image

Autoimmune Disease Testing Market - Forecast from 2026 to 2031

  • Report
  • 148 Pages
  • Global
From
In Vitro Diagnostics Market Size, Share & Trends Analysis Report by Product, End Use, Technology, Test Location, Application, Region, and Segment Forecasts, 2026-2033 - Product Image

In Vitro Diagnostics Market Size, Share & Trends Analysis Report by Product, End Use, Technology, Test Location, Application, Region, and Segment Forecasts, 2026-2033

  • Report
  • 320 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.